Efficacy and Safety of Dapagliflozin in Children With Proteinuria

Efficacy and Safety of Dapagliflozin in Non-diabetic Children With Proteinuria

The purpose of the study is to investigate the antiproteinuric effect of Dapagliflozin in children with proteinuria.

Inclusion Criteria:

• Age 6 years to 18 years;
• Urinary protein excretion > 0.2g in a 24-hr urine collection;
• eGFR≥60 ml/min/1.73m2;
• No history of diabetes;
• On stable doses of ACE inhibitors or angiotensin receptor blockers (ARBs) for > 1 month;

Exclusion Criteria:

• Receiving immunosuppressive therapy within three months prior to enrolment.
• Blood pressure less than 5th percentile of the same gender, age, and height -
• Leukocyte and/or nitrite positive urinalysis that is untreated;
• History of organ transplantation, cancer, liver disease;
• Evidence of hepatic disease as determined by any one of the following: ALT or AST values exceeding 3x ULN at the screening visit;
• History of noncompliance to medical regimens or unwillingness to comply with the study protocol.